Effect of Bortezomib Therapy Combined with Lenalidomide in Multiple Myeloma and Its Effect on Serum Inflammatory Factors
Objective To analyze the effect of bortezomib therapy combined with lenalidomide in the treatment of mul-tiple myeloma.Methods A total of eighty patients with multiple myeloma in People's Hospital of Xintai from August 2019 to December 2023 were objectively selected,and forty patients treated with bortezomib+dexamethasone were selected as the control group;and forty patients treated with bortezomib+dexamethasone+lenalidomide were se-lected as the study group.Two groups of biochemical indexes,immune indexes,inflammatory factors and adverse reac-tions were compared before and after treatment.Results After treatment,the study group β-2-microglobulin level was(3.89±0.19)µg/mL,the monoclonal protein level was(23.64±3.15)g/L,the proportion of myeloma cells was(13.92±2.68)%,better than(6.25±0.25)µg/mL,(28.93±3.23)g/L,(17.38±2.59)%in the control group,the differences were statistically significant(t=14.426,7.241,4.5.908,all P<0.05).After treatment,the immune indexes in the study group were lower than those in the control group,the differences were statistically significant(all P<0.05).There was no sta-tistically significant difference in adverse events between two groups(P>0.05).After treatment,the level of inflamma-tory factors in the study group were lower than those in the the control group,the differences were statistically signifi-cant(all P<0.05).Conclusion Bortezomib therapy combined with lenalidomide for multiple myeloma can improve bio-chemical parameters,improve patient immune function,and reduce inflammatory response without increasing adverse effects.
NETL
NSTL
万方数据
